MyoKardia

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The Company's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Size (employees)
78 (est)+28%
MyoKardia is headquartered in South San Francisco, US

Key People at MyoKardia

Charles Homcy

Charles Homcy

Interim CEO and Board Member

MyoKardia Office Locations

MyoKardia has an office in South San Francisco
South San Francisco, US (HQ)
333 Allerton Ave

MyoKardia Data and Metrics

MyoKardia Financial Metrics

USD

Net income (Q1, 2017)

(11.5 m)

EBIT (Q1, 2017)

(11.8 m)

Market capitalization (22-Aug-2017)

1.4 b

Cash (31-Mar-2017)

135.6 m
MyoKardia's current market capitalization is $1.4 b.
USDFY, 2015FY, 2016

R&D expense

28.4 m36.2 m

General and administrative expense

9 m16.3 m

Operating expense total

37.4 m52.5 m

EBIT

(23.2 m)(13.3 m)

Interest income

47 k153 k

Net Income

(22.9 m)(13.2 m)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

6.7 m8.1 m9.3 m8.8 m11.9 m

General and administrative expense

2.3 m3.9 m4.1 m4 m5.5 m

Operating expense total

9 m12 m13.3 m12.8 m17.4 m

EBIT

(5.4 m)(8.4 m)(9.8 m)(9.3 m)(11.8 m)

Interest income

20 k26 k33 k221 k

Net Income

(11.5 m)
USDFY, 2015FY, 2016

Cash

112.3 m135.8 m

Accounts Receivable

18.5 m

Inventories

1.3 m1.4 m

Current Assets

113.5 m186.3 m

PP&E

2.7 m2.8 m

Total Assets

116.6 m201.3 m

Accounts Payable

2.1 m1.8 m

Current Liabilities

22 m33 m

Total Liabilities

55.9 m

Additional Paid-in Capital

158.6 m223.2 m

Retained Earnings

(64.7 m)(77.8 m)

Total Equity

93.9 m145.4 m

Financial Leverage

1.2 x1.4 x
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

64.5 m99.5 m87.6 m77.1 m135.6 m

Current Assets

65.2 m100.7 m88.7 m77.9 m149.4 m

PP&E

2.9 m3 m2.9 m2.7 m2.6 m

Total Assets

70.1 m104 m91.9 m81.4 m184.4 m

Accounts Payable

1.7 m2 m1.7 m1.7 m2.4 m

Current Liabilities

19.9 m17.5 m14.3 m12.2 m31.9 m

Additional Paid-in Capital

159 m159.9 m160.7 m224.7 m

Retained Earnings

(56.2 m)(73.1 m)(82.9 m)(92.1 m)(89.4 m)

Total Equity

85.9 m77.1 m68.6 m135.2 m

Financial Leverage

1.2 x1.2 x1.2 x1.4 x
USDFY, 2015FY, 2016

Net Income

(22.9 m)(13.2 m)

Depreciation and Amortization

965 k1.1 m

Inventories

(852 k)(112 k)

Accounts Payable

1.3 m(434 k)

Cash From Operating Activities

(32.1 m)(20.9 m)

Purchases of PP&E

(1.4 m)(1.1 m)

Cash From Investing Activities

(1.3 m)(17.1 m)

Cash From Financing Activities

102 m61.5 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(11.5 m)

Accounts Payable

1.7 m2 m1.7 m1.7 m2.4 m
Y, 2017

Financial Leverage

1.4 x

MyoKardia Market Value History

Traffic Overview of MyoKardia

MyoKardia Online and Social Media Presence

MyoKardia Company Life and Culture

You may also be interested in